REINCA: Clinical Value of Heart Rate Variability Indexes to Predict Outcomes After Exercise Training in Chronic Heart Failure

Sponsor
Universidad de la Republica (Other)
Overall Status
Completed
CT.gov ID
NCT02903225
Collaborator
(none)
40
2
55

Study Details

Study Description

Brief Summary

Controlled exercise training is a valuable therapeutic addition to pharmacological treatment in most patients with chronic heart failure, reducing long-term mortality, preventing cardiac remodeling and improving functional capacity. Despite the mechanism underlying its benefits might be multifactorial, a sustained improvement in autonomic balance is usually attributed as a major effect. Nevertheless, not all eligible subjects show the same response to exercise, probably due to several differences in the subpopulations enrolled. The investigators hypothesize that some Heart Rate Variability indexes could be valid tools to optimize the selection and follow-up of chronic heart failure patients to training

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Cardiac Rehabilitation
Phase 4

Detailed Description

Forty subjects followed in a University Heart Failure Management Program were prospectively included. All patients were evaluated before the randomization and after 24 weeks from enrollment. The investigators performed a detailed anamnesis and complete physical examination, Doppler echocardiography, Stress Testing, 6-minute walk test, heart rate variability analysis, and quality of life test. Patients were randomized either to a training group: performing a supervised training program, or a control group receiving usual care. All patients received an optimal pharmacologic treatment including diuretics, angiotensin converting enzyme inhibitors or angiotensin receptor blockers and beta-adrenergic blocking agents. All patients included in the training group attended a supervised program 3-days/week during 24 weeks (68-74 sessions). Physical aerobic training appears to impart beneficial changes in autonomic control of patients with chronic heart failure through both parasympathetic and sympathetic control of hear rate. These effects produce changes in several Heart Rate Variability indices as HF and rMSSD related with parasympathetic tone.

Study Design

Study Type:
Interventional
Actual Enrollment :
40 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
Clinical Value of Heart Rate Variability Indexes to Predict Outcomes After Exercise Training in Chronic Heart Failure
Study Start Date :
Apr 1, 2010
Actual Primary Completion Date :
Nov 1, 2013
Actual Study Completion Date :
Nov 1, 2014

Arms and Interventions

Arm Intervention/Treatment
No Intervention: Usual Care

usual care and no changes in their previous physical activity

Active Comparator: Cardiac Rehabilitation

Exercise Training program on a 3-days/week basis during 24 weeks (68-74 sessions). Each session started with a 10-min warm-up walking period followed by 20-min of breathing exercises and free non-resistance movements of limbs. This stage was followed by pedaling during 20-minutes at a circuit resistance training protocol using a stationary cycle-ergometer. Each session ended with a cool down period (5-minutes) including diverse stretching maneuvers of engaged muscle groups. The initial bicycle-ergometer workload (WL) was defined as 50% of the maximum achieved in the previous stress testing

Behavioral: Cardiac Rehabilitation
All patients included in this group attended a supervised exercise training program. A cardiologist supervised the hole training sessions. Blood pressure, pulse rate, oxygen saturation, and body weight were measured in each session. The modified Borg scale was used to measure the perceived exercise intensity
Other Names:
  • Exercise training
  • Educational approach
  • Outcome Measures

    Primary Outcome Measures

    1. Clinical Events [6 month]

      Change in New York Heart Association Functional Class; Number of hospitalizations 6 months before and after the date of enrollment; temporary or permanent withdrawal from the study protocol (due to persistent atrial or ventricular arrhythmias; worsening of congestive heart failure symptoms; myocardial infarction; unstable angina; need of cardiac interventions: pacemaker, implantable cardioverter defibrillator, coronary revascularization or cardiac transplantation; stroke or transient ischemic attack; severe peripheral intermittent claudication or death observed during training or follow-up sessions

    2. Mean heart rate [6 month]

      the mean value of the12-min Electrocardiogram-recordings was considered the resting heart rate (beats per minute)

    3. 6 minute walk test [6 month]

      walking along a 20-meter long corridor at their own pace, with the aim of covering as much ground as possible in 6 minutes. The distance walked was expressed in meter

    4. left ventricular ejection fraction [one year]

      The area-length method was measured to obtain biplane left ventricle volumes. Left Ventricle ejection fraction was derived from the standard equation (%)

    5. quality of life [6 month]

      All the subjects completed the Short-Form 36 Health Survey (SF-36), available in its Spanish version, for measuring physical and mental quality of life

    6. Stress Test [6 month]

      symptom limited exercise testing, measured in metabolic unit (MET)

    7. square root of the mean squared successive differences of R-R intervals (rMSSD) [6 month]

      short-term continuous electrocardiographic recordings were performed for heart rate variability analysis. In the time domain, the square root of the mean squared successive differences of R-R intervals (rMSSD) were calculated. Units: ms

    8. Heart rate power high-frequency (HF) [6 month]

      The high-frequency (HF), from 0.15 to 0.40 Hz of the power spectral analysis were calculated. Units: ms2/Hz

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 80 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • subjects followed in a University Heart Failure Management Program

    • maintained sinus rhythm

    • New York Heart Association Functional Class (NYHA) I to III and

    • LVEF≤40% documented by echocardiogram

    • optimal pharmacologic treatment

    Exclusion Criteria:
    • history of stroke, myocardial infarction or extended anterior myocardial scar

    • revascularization procedures or recurrent angina within previous 3 months

    • orthopedic impairment

    • alcohol or drug abuse;

    • implant of pacemaker or cardioverter-defibrillator (AICD);

    • frequently ventricular dysrhythmias,

    • atrial flutter or fibrillation

    • insulin-dependent diabetes mellitus;

    • severe chronic obstructive pulmonary disease or renal dysfunction

    • comorbid non-cardiac disease limiting short term survival

    • previous enrollment in an ET program

    • subjects at great propensity for noncompliance

    Contacts and Locations

    Locations

    No locations specified.

    Sponsors and Collaborators

    • Universidad de la Republica

    Investigators

    • Principal Investigator: Roberto Ricca-Mallada, MD MSc, Hospital de Clinicas

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Roberto Ricca-Mallada, Medical Doctor, Magister in Science, Universidad de la Republica
    ClinicalTrials.gov Identifier:
    NCT02903225
    Other Study ID Numbers:
    • CARDIAC REHABILITATION HF
    First Posted:
    Sep 16, 2016
    Last Update Posted:
    Sep 16, 2016
    Last Verified:
    Sep 1, 2016
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Keywords provided by Roberto Ricca-Mallada, Medical Doctor, Magister in Science, Universidad de la Republica
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Sep 16, 2016